Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Sales

Burning Rock Biotech (BNR) EBIT Margin: 2019-2025

Historic EBIT Margin for Burning Rock Biotech (BNR) over the last 7 years, with Sep 2025 value amounting to -9.24%.

  • Burning Rock Biotech's EBIT Margin fell 1186.00% to -9.24% in Q3 2025 from the same period last year, while for Sep 2025 it was -16.23%, marking a year-over-year increase of 4209.00%. This contributed to the annual value of -69.32% for FY2024, which is 5522.00% up from last year.
  • Latest data reveals that Burning Rock Biotech reported EBIT Margin of -9.24% as of Q3 2025, which was up 1.03% from -9.34% recorded in Q2 2025.
  • In the past 5 years, Burning Rock Biotech's EBIT Margin ranged from a high of 2.62% in Q3 2024 and a low of -203.45% during Q2 2022.
  • For the 3-year period, Burning Rock Biotech's EBIT Margin averaged around -70.02%, with its median value being -82.06% (2024).
  • In the last 5 years, Burning Rock Biotech's EBIT Margin plummeted by 9,049bps in 2021 and then soared by 14,279bps in 2024.
  • Burning Rock Biotech's EBIT Margin (Quarterly) stood at -170.61% in 2021, then crashed by 1,234bps to -182.95% in 2022, then soared by 6,297bps to -119.98% in 2023, then surged by 4,455bps to -75.43% in 2024, then crashed by 1,186bps to -9.24% in 2025.
  • Its EBIT Margin was -9.24% in Q3 2025, compared to -9.34% in Q2 2025 and -11.41% in Q1 2025.